BioMarin Manufacturing Ireland is to create 50 new jobs at its Dublin Global Commercial Operation Hub. The company will be recruiting staff for senior accounting, finance, customer service and marketing positions.
The company is a subsidiary of BioMarin Pharmaceuticals.
BioMarin also announced this week that the European Commission granted approval of VIMIZIM, an enzyme replacement drug for the treatment of MPS IVA, a lysosomal storage disorder.
The Dublin operation has responsibility for international supply chain, logistics and high level commercial decision-making, including price, distribution and third-party contracts for the launch of VIMIZIM.
The expansion complements the growth in BioMarin’s biopharma manufacturing facility in Shanbally, Co Cork, which is expected to grow to 140 employees by 2015 to support the anticipated commercial demand of VIMIZIM.
BioMarin expects to have a combined total employment of about 200 people in Ireland by the end of 2017.
A strategic win
“Today’s announcement that BioMarin is expanding its operations in Dublin and creating 50 jobs is a further boost for the sector and for the city and I look forward to working with BioMarin as they develop their plants in Dublin and Cork,” said Richard Bruton, Minister for Jobs, Enterprise and Innovation.
BioMarin VP and general manager in charge of commercial operations for BioMarin EUMEA James Lennertz said Ireland is an ideal business environment for the company.
“Ireland lets us focus on what we do best – targeting diseases such as Morquio A syndrome that lack effective drug therapies and affect relatively few people, many of whom are children. The expansion of BioMarin’s Global Commercial Operation in Dublin is an essential part of our strategy in providing therapies that are the first or best of their kind.”
The IDA said the project was an important strategic win in terms of the growing cluster of speciality pharma companies and high-end business services that are locating in Ireland.
“The proposed expansion is a positive development for BioMarin to increase its footprint in Ireland,” said IDA Ireland chief executive Barry O’Leary. “I look forward to continue to work closely with BioMarin as it further embeds its operations in Ireland.”
Investment image via Shutterstock